Advertisement

 

 

An update on small molecules targeting CXCR4 as starting points for the development of anti-cancer therapeutics.

An update on small molecules targeting CXCR4 as starting points for the development of anti-cancer therapeutics.
Author Information (click to view)

Grande F, Giancotti G, Ioele G, Occhiuzzi MA, Garofalo A,


Grande F, Giancotti G, Ioele G, Occhiuzzi MA, Garofalo A, (click to view)

Grande F, Giancotti G, Ioele G, Occhiuzzi MA, Garofalo A,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

European journal of medicinal chemistry 2017 08 12139() 519-530 pii 10.1016/j.ejmech.2017.08.027

Abstract

CXCR4 (C-X-C Chemokine Receptor type 4) and its natural ligand SDF-1α (Stromal-Derived-Factor-1α) are involved in a number of physiological and pathological processes including cancer spread and progression. Over the past few years, numerous CXCR4 antagonists have been identified and currently are in different development stages as potential agents for the treatment of several diseases involving the CXCR4/SDF-1α axis. Herein, we focus on small molecules reported in literature between 2013 and 2017, claimed as CXCR4 antagonists and potentially useful in the treatment of cancer and other diseases where this receptor is involved. Most of the compounds resulted from a chemical optimization of previously identified molecules and some of them could represent suitable candidates for the development of advanced anticancer agents.

Submit a Comment

Your email address will not be published. Required fields are marked *

two + 6 =

[ HIDE/SHOW ]